RSHN (RushNet) EV-to-EBIT: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RushNet EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RushNet's Enterprise Value is $0.85 Mil. RushNet does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate RushNet's EV-to-EBIT at this moment.

The historical rank and industry rank for RushNet's EV-to-EBIT or its related term are showing as below:

RSHN's EV-to-EBIT is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 23.9
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. RushNet's Enterprise Value for the quarter that ended in . 20 was $0.00 Mil. RushNet does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate RushNet's Earnings Yield (Joel Greenblatt) % at this moment.

RushNet  (OTCPK:RSHN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

RushNet's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 ) =EBIT / Enterprise Value (Q: . 20 )
=/
= %

RushNet EV-to-EBIT Related Terms

RushNet EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for RushNet's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RushNet EV-to-EBIT Chart

RushNet Annual Data
Trend
EV-to-EBIT

RushNet Quarterly Data
EV-to-EBIT

RSHN vs MOJO, LBIX, KRED: EV-to-EBIT Comparison

For the Diagnostics & Research subindustry, RushNet's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RushNet EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RushNet's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RushNet's EV-to-EBIT falls into.


RushNet EV-to-EBIT Calculation

RushNet's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.849/
=

RushNet Business Description

Address 8465 Merchants Way, Suite 206, Orange Park, FL, USA, 32222
RushNet Inc through its subsidiary heliosDX, a National Clinical Reference Laboratory offers High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The firm provides physicians with individualized customer service, as well as fast and accurate reporting of results. The company invests in its infrastructure with the most efficient scientific proven instruments and the latest software for patient and physician satisfaction. It allows heliosDX to provide physicians with fast and accurate reporting meetings. The firm excels in patient and client care through physician-designed panels that aid in testing compliance and reporting education.